BCR-Abl Kinase Domain Mutations (IRMA)

Overview

Detection of mutationin the Kinase domain of BCR-ABL and can have therapeutic indication. Also called as IRMA (Imatinib Resistance Mutation Analysis). This test is useful for detecting over 90 known and novel mutations in ABL kinase domain of Ph chromosome for resistance to Imatinib in CML patients.